Is there a survival advantage of oral immunonutrition in head and neck cancer?

Affiliations

¹ Department of Surgery, Queen's Medical Centre, Nottingham University Hospital NHS Trust, Nottingham, United Kingdom.
² Department of Gastroenterology, Derriford Hospital, Plymouth, United Kingdom.

Free article

Comment

Alfred Adiamah et al. Am J Clin Nutr. 2020.

Free article

. 2020 Dec 10;112(6):1427-1428.

doi: 10.1093/ajcn/nqaa306.

¹ Department of Surgery, Queen's Medical Centre, Nottingham University Hospital NHS Trust, Nottingham, United Kingdom.
² Department of Gastroenterology, Derriford Hospital, Plymouth, United Kingdom.

No abstract available

Comment on

A double-blind phase III trial of immunomodulating nutritional formula during adjuvant chemoradiotherapy in head and neck cancer patients: IMPATOX.
Boisselier P, Kaminsky MC, Thézenas S, Gallocher O, Lavau-Denes S, Garcia-Ramirez M, Alfonsi M, Cupissol D, de Forges H, Janiszewski C, Geoffrois L, Sire C, Senesse P; Head and Neck Oncology and Radiotherapy Group (GORTEC). Boisselier P, et al. Am J Clin Nutr. 2020 Dec 10;112(6):1523-1531. doi: 10.1093/ajcn/nqaa227. Am J Clin Nutr. 2020. PMID: 32936874 Clinical Trial.